Rituximab for immune hemolytic anemia following T- and B-cell-depleted hematopoietic stem cell transplantation

被引：23

作者：

Corti, P

Bonanomi, S

Vallinoto, C

Balduzzi, A

Uderzo, C

Cazzaniga, G

Gaipa, G

Dassi, M

Perseghin, P

Rovelli, A

机构：

[1] Univ Milano Bicocca, Ctr Trapianto Midollo Osseo, Osped San Gerardo, I-20052 Monza, Italy

[2] Univ Milano Bicocca, Fdn Tettamanti, Osped San Gerardo, Pediat Clin, I-20052 Monza, Italy

[3] Univ Milano Bicocca, Serv Immunoematol & Transfus, Osped San Gerardo, Lab Ematol, I-20052 Monza, Italy

来源：

ACTA HAEMATOLOGICA | 2003年 / 109卷 / 01期

关键词：

hematopoietic stem cell transplantation; storage diseases; Hurler syndrome; immune hemolytic anemia;

D O I：

10.1159/000067271

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The treatment of immune-mediated hemolytic anemia (IHA) complicating hematopoietic stem cell transplantation (HSCT) is often unsatisfactory. We report a case of IHA which occurred after T- and B-cell depleted unrelated donor HSCT carried out for mucopolysaccharidosis type I-H (Hurler syndrome) which was successfully treated with anti-CD20+ monoclonal antibody Copyright (C) 2003 S. Karger AG, Basel.

引用

收藏

页码：43 / 45

页数：3

相关论文

共 12 条

[1] Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease [J].

Berentsen, S ;

Tjonnfjord, GE ;

Brudevold, R ;

Gjertsen, BT ;

Langholm, R ;

Lokkevik, E ;

Sorbo, JH ;

Ulvestad, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :79-83

[2] Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant [J].

Chen, FE ;

Owen, I ;

Savage, D ;

Roberts, I ;

Apperley, J ;

Goldman, JM ;

Laffan, M .

BONE MARROW TRANSPLANTATION, 1997, 19 (05) :491-495

[3]

Coiffier B, 1998, BLOOD, V92, P1927

[4] Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions [J].

Cwynarski, K ;

Goulding, R ;

Pocock, C ;

Dazzi, F ;

Craddock, C ;

Kaeda, J ;

Olavarria, E ;

Kanfer, E ;

Apperley, J ;

Lawler, M ;

Goldman, JM .

BONE MARROW TRANSPLANTATION, 2001, 28 (06) :581-586

[5]

Drobyski WR, 1996, BONE MARROW TRANSPL, V17, P1093

[6] Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation [J].

McGuirk, JP ;

Seropian, S ;

Howe, G ;

Smith, B ;

Stoddart, L ;

Cooper, DL .

BONE MARROW TRANSPLANTATION, 1999, 24 (11) :1253-1258

[7] Treatment of childhood autoimmune haemolytic anaemia with rituximab [J].

Quartier, P ;

Brethon, B ;

Philippet, P ;

Landman-Parker, J ;

Le Deist, F ;

Fischer, A .

LANCET, 2001, 358 (9292) :1511-1513

[8] Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia [J].

Seeliger, S ;

Baumann, M ;

Mohr, M ;

Jürgens, H ;

Frosch, M ;

Vormoor, J .

EUROPEAN JOURNAL OF PEDIATRICS, 2001, 160 (08) :492-496

[9] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura [J].

Stasi, R ;

Pagano, A ;

Stipa, E ;

Amadori, S .

BLOOD, 2001, 98 (04) :952-957

[10] Rituximab for myasthenia gravis developing after bone marrow transplant [J].

Zaja, F ;

Russo, D ;

Fuga, G ;

Perella, G ;

Baccarani, M .

NEUROLOGY, 2000, 55 (07) :1062-1063